Sponsored Links
| Cormedix Announces Successful Completion Of Patient Recruitment In Phase II Contrast-Induced Acute Kidney Injury Study With CRMD001 |
 |
 |
 |
| Medical News - Cardiovascular and Cardiology | |||
|
CorMedix Inc. ("CorMedix") (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced it successfully completed patient enrollment in its phase II Contrast-Induced Acute Kidney Injury ("CI-AKI") study with its oral drug candidate CRMD001... Read more: Cardiovascular / Cardiology News From Medical News Today
|